Shreya Life Sciences Pvt Ltd of Mumbai has introduced world's first buccal insulin spray under the brand name Oral-Recosulin. Shreya Life Sciences has achieved this major success with the help of US-based Generex Biotechnology Corporation. The insulin spray will be helpful in treating type-1 and type-2 diabetes patients. Generex Biotechnology has used its special technology to develop his spray insulin. According to chairman and managing director of Shreya Life Sciences, Sujit Kumar Singh, each pack of Oral-Recosulin will be available at a cost of Rs 2200.

 

Oral-Recosulin regulates prandial glucose rapidly within five to 10 minutes of intake. The medicine then last for duration of 120 to 150 minutes. The major advantage of this insulin spray is that the diabetes patients will no longer need to take injections. Apart from it, the spray operates very rapidly once consumed by the patients. According to a company source of Shreya Life Sciences, spray insulin will provide simple solution for worldwide diabetes problem.

 

Generex Biotechnology Corporation will market the product in US market under the name of Oral-lyn. Under deal, Shreya Life Sciences will provide the insulin crystals while the buccal device will be supplied by Generex Biotechnology Corporation. The new product is supposed to earn considerable profit in India where diabetes disease crop up in every other family.